AXS-07 (MoSEIC™ Meloxicam/Rizatriptan): Novel Oral Therapeutic in Clinical Development for the Acute Treatment of Migraine
International Headache Society [IHC], September 2019
Efficacy and Safety of AXS-05, an Oral NMDA Receptor Antagonist with Multimodal Activity, in Major Depressive Disorder: Results of a Phase 2, Double-Blind, Active-Controlled Trial
American Society of Clinical Psychopharmacology [ASCP], May 2019
Efficacy and Safety of AXS-05, an Oral NMDA Receptor Antagonist with Multimodal Activity, in Major Depressive Disorder: Results of a Phase 2, Double-Blind, Active-Controlled Trial (Oral Presentation)
American Society of Clinical Psychopharmacology [ASCP], May 2019
AXS-05: A Mechanistically Novel Oral Therapeutic in Development for Neuropsychiatric Disorders
American Psychiatric Association Conference [APA], May 2019
AXS-05 (Dextromethorphan/Bupropion): An Innovative Treatment in Clinical Development for Agitation Associated with Alzheimer’s Disease
Alzheimer's Association International Conference [AAIC], July 2018
AXS-05 for Neuropsychiatric Disorders: Scientific Rationale and Clinical Development
American Society of Clinical Psychopharmacology [ASCP], May 2018
Clinical Development of AXS-05 for Treatment Resistant Depression and Agitation Associated with Alzheimer’s Disease
American Psychiatric Association Conference [APA], May 2018